Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Relapsed/Refractory CLL
NCT00290810Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2005
- Primary completion
- Oct 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in chronic lymphocytic leukemia (CLL), sponsored by National Cancer Institute. Started Dec 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00290810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290810.